Syros Pharmaceuticals
在场
Syros Pharmaceuticals 是一家在股票代码 SYRS (US) 下上市的公司。
涉及Syros Pharmaceuticals的并购和融资。
- Syros Pharmaceuticals has announced the acquisition of Tyme Technologies (公布2022十一月29号).
- Syros Pharmaceuticals 刚刚宣布为 190 筹款数百万美元。 (公布2022七月5号).
- Syros Pharmaceuticals has announced the acquisition of Tyme Technologies (公布2022七月5号).
高管
查看带有其 17 名主要高管的组织结构图
Syros Pharmaceuticals 搜索最多的简介
高管在Syros Pharmaceuticals变化
- Nancy Simonian 曾任 Director, President, Chief Executive Officer and Principal Financial Officer, 将于 202312月2 现任 Director (新闻发布的2023十月3号).
- Conley Chee 曾任 Chief Commercial Officer, 将于 202312月2 升职为 Chief Executive Officer (新闻发布的2023十月3号).
创建提醒
跟踪 Syros Pharmaceuticals 的高管变动
药店
Syros Pharmaceuticals 拥有 1,861 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- MedMen has filed for bankruptcy protection (公布2024四月28号).
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
药店 行业的其他推荐联系人
消息
Syros Pharmaceuticals 的最新新闻稿
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update :: Syros Pharmaceuticals, Inc. (SYRS)
- Press Releases :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros to Participate in TD Cowen 44th Annual Health Care Conference :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants :: Syros Pharmaceuticals, Inc. (SYRS)
- Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine :: Syros Pharmaceuticals, Inc. (SYRS)
- View more press releases Close
通过电子邮件
